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Background: Tuberculosis is a major global public health challenge, and a majority of countries have adopted a
version of the global strategy to fight Tuberculosis, Directly Observed Treatment, Short Course (DOTS). Drawing on
results from research in Ethiopia and Norway, the aim of this paper is to highlight and discuss ethical aspects of the
practice of Directly Observed Treatment (DOT) in a cross-cultural perspective.
Discussion: Research from Ethiopia and Norway demonstrates that the rigid enforcement of directly observed
treatment conflicts with patient autonomy, dignity and integrity. The treatment practices, especially when imposed
in its strictest forms, expose those who have Tuberculosis to extra burdens and costs. Socially disadvantaged
groups, such as the homeless, those employed as day labourers and those lacking rights as employees, face the
highest burdens.
Summary: From an ethical standpoint, we argue that a rigid practice of directly observed treatment is difficult to
justify, and that responsiveness to social determinants of Tuberculosis should become an integral part of the
management of Tuberculosis.
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Tuberculosis (TB) is a major public health concern with
8.8 million new cases and 1.4 million deaths globally in
2010 [1]. In the mid-1980s TB attracted increased global
interest because of the growing number of cases and an
alarming rise in multidrug resistant cases in the industri-
alized part of the world [2,3]. Although drug resistant
strains had been diagnosed previously in high-endemic
settings, multidrug resistance was a new problem in the
industrialized world. In 1991, the World Health Org-
anization (WHO) set two targets for national TB control
programmes: to detect at least 70% of all new sputum
smear-positive cases arising each year and to cure at
least 85% of them [4]. Essential methods for TB diagno-
sis and treatment were integrated into the WHO’s new
TB control strategy, Directly Observed Treatment, Short
Course (DOTS). Avoiding interruption of TB treatment
was considered one of the major challenges in preventing
the spread of drug resistance. To prevent further* Correspondence: mette.sagbakken@hioa.no
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distribution, and reproduction in any mediumdevelopment of resistance against anti-TB drugs, the ex-
tensive DOTS strategy centred on controlling each patient
taking their daily dose of medication [5].
Most countries have now adopted a version of DOTS.
In 2007, 86% of patients were treated successfully. This
was the first time the target of 85% had been exceeded
at a global level since it was set in 1991 [6]. Neverthe-
less, studies investigating the effect of DOTS on TB inci-
dence, treatment completion and cure do not provide
convincing evidence of the value of DOTS as the main
strategy in efforts to control TB. In areas where there
has been a significant decline of TB, it has been difficult
to separate the effect of DOTS from the effect of general
socio-economic development [7]. A study of trends in
TB incidence and their determinants in 134 countries
found that the incidence declined more quickly in
countries that had a higher human development index,
greater health expenditure, lower child mortality and im-
proved sanitation [8]. Incidence rates declined more
quickly in high-income countries with lower immigra-
tion and in countries with lower HIV infection rates.
While DOTS programmes have significantly contributed
to a decline in TB prevalence and TB mortality, socio-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the decline in TB incidence in different regions of the
world [9].
Directly observed treatment (DOT) is one component
of DOTS. It involves observing patients during their in-
take of medication. A systematic review of 11 randomized
and quasi-randomized controlled trials that compared
DOT conducted by a health worker, family member, or
community volunteer with self-administration of treat-
ment at home found no evidence that DOT, when com-
pared with self-administration, had any quantitatively
important effect on cure or treatment completion for TB
in low-, middle- and high-income countries [10]. Further,
no significant difference in clinical outcomes was found
between DOT given at a clinic and DOT given by a family
member or community health worker, or for DOT given
by a family member compared with a community health
worker [10].
The impact of DOT on patients’ autonomy has been
questioned [11]. In 2004, the International Union Against
Tuberculosis and Lung Disease (IUATLD) appointed an
ethics advisory group to develop policies and operational
guidelines based on the Helsinki Declaration [12]. In
2008, the WHO’s Ethics and Health Team established a
WHO task force to address ethical issues in TB care and
control programmes. In 2010, the WHO published Guid-
ance on Ethics of Tuberculosis Prevention, Care and Con-
trol to guide stakeholders in implementing TB control
programmes [13]. These guidelines emphasize the over-
arching goals of TB care and control programmes, which
are:
– to achieve universal access to high-quality diagnosis
and patient-centred treatment
– to reduce the human suffering and socio-economic
burden associated with TB
– to protect poor and vulnerable populations from TB,
TB/HIV and MDR-TB
– to support development of new tools and enable
their timely and effective use
– to protect and promote human rights in TB
prevention, care and control.
The guideline identifies ethical values that are import-
ant to TB care and control, such as “social justice and
equity” (addressing underlying root causes and existence
of inequalities in society), “common good” (meaning inter-
ventions should benefit whole communities), “respect for
patient autonomy”, “participation” and “transparency” in
decision-making processes, and “effectiveness” [13].
Research in Addis Ababa, Ethiopia [14,15], and in
Norway [16,17], indicates that DOT gives rise to a series
of ethical issues in practice. The aim of this paper is to
highlight and discuss ethical aspects of the practice ofDOT from a cross-cultural perspective, drawing on re-
sults from research in Ethiopia and Norway.
Discussion
We first give an account of some frameworks commonly
used to assess ethical issues in public health interven-
tions. We then expand the ethical perspective by includ-
ing a social justice framework.
Ethical frameworks in public health
The ethical values articulated in the Guidance on Ethics of
Tuberculosis Prevention, Care and Control reflect many of
the principles incorporated in frameworks used by ethi-
cists in assessing the justification of public health inter-
ventions. These frameworks include a loose set of moral
considerations such as producing benefits, preventing
harms and maximizing utility, and, to a great extent, they
overlap [18-20]. Childress et al. [18] point to five “justifica-
tory conditions” that need to be assessed when consider-
ing ethical concerns in public health interventions. These
conditions are intended to help decide whether public
health measures can legitimize overriding moral values
such as individual liberty and justice. One condition is “ef-
fectiveness”, implying that any infringement of one or
more moral considerations should be based on public, sci-
entific evidence that the proposed intervention will do
more good than harm. Another condition is “proportion-
ality”, implying that the benefits of any proposed interven-
tion should outweigh any negative features and effects,
such as infringement of patient autonomy. Related to this
is “necessity”, meaning that any intervention that raises
moral concerns should not go beyond what is necessary to
achieve its goal. Even when a proposed policy satisfies the
first three justificatory conditions, “least infringement” is a
condition underlining the need to minimize the infringe-
ment on general moral considerations. For example, when
a policy infringes on a patient’s autonomy, the least re-
strictive alternative should be sought; or when a policy in-
fringes on a patient’s privacy, the least intrusive alternative
should be sought. Lastly, “public justification” is needed
when public health agents implement practices or policies
that infringe on one or several moral considerations. This
justification implies the responsibility to explain and jus-
tify the necessity of the infringement in a solid and trans-
parent way to the public [18].
Upshur [20] introduces a set of principles for public
health agents to be used for systematic reflection on ethical
issues in the practice of public health, and which emphasize
the principles of harm, least restrictive means and transpar-
ency. These principles overlap with Childress’ five condi-
tions, but Upshur also draws attention to the principle of
reciprocity. He underlines that if burdens are imposed on a
person in order to comply with a public health request,
then the community should reciprocate by ensuring that
Sagbakken et al. BMC Medical Ethics 2013, 14:25 Page 3 of 10
http://www.biomedcentral.com/1472-6939/14/25such burdens, such as the use of time or income, are mini-
mized or compensated for. Kass [19] emphasizes that even
if evidence of effectiveness does exist, one must identify
the known or potential burdens or harms caused by a
programme. Such burdens or harms will fall into three
main categories: risks related to privacy/confidentiality;
risks related to liberty/self-determination; and risks
related to justice (such as undue burdens imposed on
particular segments of the society). One has to ask
whether burdens can be minimized or if alternative
approaches exist. If more than one option exists to
address a public health problem, we are, according to
Kass, obliged to choose the approach that represents
the least risk to other moral claims, such as liberty,
opportunities, privacy and justice. Health professionals
thus have a responsibility to identify and advocate for
the removal of health programmes that are unethical,
whether because of lack of data demonstrating effective-
ness, discriminatory procedures or unjustified restric-
tions on patients’ liberties. Kass [19] underlines the
need to discuss whether public health programmes have
any role in addressing existing injustices, and relates
this to the strong correlation between poor living condi-
tions and poor health outcomes.
A social justice framework
John Rawls [21] claims that justice implies distributing
resources unequally to help those that are least well off.
From a social justice perspective all lives have equal
value, implying a moral justification for a fair allocation
of resources. Rawls’ framework requires preferential treat-
ment for the most disadvantaged. In other words, justice
would imply the use of policies that seek to safeguard the
interests of all members in the community. If an uneven
distribution is avoidable it may be considered unjust and
unfair, and health inequalities then take on a moral and
ethical dimension [13]. The social justice perspective chal-
lenges bioethics and medical ethics by claiming that cen-
tral ethical topics need to be “re-socialised”. This means
that market justice must be replaced by a rights-based
principle of justice [22,23]. The social justice perspective
may imply a criticism of ethics for not engaging in how in-
equalities of all kinds are linked to the same structural
forces studied by anthropologists, sociologists and epide-
miologists. By not engaging in how health inequalities
may be prevented, ethics serves to legitimize an extrava-
gant belief in the efficacy of medical treatment [22].
The social justice perspective draws attention to the root
causes of diseases and the existence of inequalities in soci-
ety [13,24]. There is increasing knowledge about how so-
cial determinants of health, or the “causes of the causes”
of ill health such as childhood conditions, globalization,
urbanization, living conditions and employment condi-
tions influence all stages of TB pathogenesis, therebycreating inequities related to exposure to infection, pro-
gression to active disease, and delayed or incorrect diag-
nosis, as well as health outcomes. A strong association
exists between TB incidence and a country’s gross domes-
tic product per capita. A strong socio-economic gradient
is also found within countries, within cities and even
across households, with the poorest having the highest
risk [7,9]. The higher risk of TB among the poor can most
likely be explained by greater exposure to some, or many,
intermediary risk factors such as HIV, under-nutrition,
crowded living and working conditions, smoking, harmful
use of alcohol, diabetes and indoor air pollution [7,25].
Marginalized or socially disadvantaged populations such
as indigenous people, ethnic minorities, migrants and
prisoners also have a higher incidence of TB [9]. Poverty
and low socio-economic status correspond with poorer
treatment outcomes, which may partly be explained by
the poor having limited access to high-quality care. How-
ever, in most countries, TB services are integrated into
existing health systems; thus it is also important to address
systemic inequities in all health systems [9].
Comparison of DOT in a low-endemic and a high-endemic
country
Research in two different countries set out to explore
patients’ and health personnel’s experiences with DOT.
One study was conducted in 2002 in Addis Ababa,
Ethiopia, where DOT was implemented in 1993 [14,15].
The other study [16,17] was conducted in 2008 in Oslo/
Akershus, Norway, where DOT was implemented in
2003. Both studies were qualitative. The study from
Ethiopia included in-depth interviews with 21 patients
with TB (10 patients undergoing TB treatment and 11
who had interrupted treatment), four relatives and five
health workers, together with two focus group discus-
sions with an additional 11 patients. In Norway, the data
were collected through in-depth interviews with 22 pa-
tients undergoing TB treatment and 20 health workers.
A large proportion of the patients in both contexts were
interviewed two or three times.
Ethiopia
In Addis Ababa, Ethiopia, all patients, without prior se-
lective appraisal, had to attend a health care facility for
DOT on a daily basis for the first two months of treat-
ment. There was no use of community or household
DOT. Many who could not afford transportation stated
that they were physically exhausted because they had to
travel anything from 30 minutes to two hours each day
to reach the clinics. All patients, even those with ad-
vanced symptoms, were told to queue up at the same
time each morning and many had to be carried or phys-
ically supported by relatives. The rigid organization of
treatment reinforced many of the following emerging
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benefit of having a permanent job or social security ben-
efits when ill, a serious illness such as TB can mean loss
of work or the inability to work as a day labourer. One
of the main problems experienced by the majority of pa-
tients in the study was loss of employment or of the op-
portunity to work during treatment. Many struggled to
find a way to retain some level of income, but the daily
clinic attendance conflicted with the possibility of regis-
tering as a day labourer in the morning or working as
maids doing household chores. Some respondents were
housewives, but the household finances were still af-
fected because their husbands lost income and risked
their jobs when escorting them to the clinic. In a group
of 10 patients followed over a six-month period, only
one patient managed to keep his (regular) job. Patients
often ended up in a downward economic spiral where
loss of employment and/or income occurred at a point
in time where many had already exhausted all their eco-
nomic resources through the diagnostic process and
where they needed extra money to cover direct (trans-
port) and indirect expenses (loss of time and income) re-
lated to daily clinic attendance. Those who struggled
most to manage treatment were the socially disadvan-
taged groups, such as the homeless, those employed as
day labourers or working in the private sector, those
lacking employee or social security rights, those who
had migrated to Addis Ababa for work or TB treatment,
single mothers, and others lacking a social support
network. Another important finding in this study was
that patients experienced that they had no power to in-
fluence how their treatment was organized, even if they
actively tried to do this. Many reported being threatened,
punished, humiliated or treated angrily by staff for not
adhering strictly to the implicit rules of the system, even
though the health workers were aware of the difficulties
patients faced in accessing daily treatment. There were
several examples of patients being denied access to treat-
ment after a period of treatment interruption.
While the data from Ethiopia were from 2002, the
most relevant findings are supported in a recent system-
atic review assessing patient costs for TB treatment and
care in sub-Saharan Africa [26]. The review shows that
TB patients and households in sub-Saharan Africa often
incur high costs when undergoing TB treatment and
care. Several of the primary studies included in the re-
view are from Ethiopia, a country where TB diagnosis
and treatment is (mainly) provided by general health
workers in health facilities. One study, assessing costs
related to pretreatment (diagnosis) and treatment for pa-
tients with TB and/or AIDS conducted in rural, urban
and peri-urban settings in Ethiopia, found that, on aver-
age, 48% of annual household income was lost because
of TB treatment [27]. Pretreatment costs, such as directcosts for diagnostic tests, represented 35% of annual
household income for TB patients. However, the main
cost throughout treatment was reported to be loss of
income. The study also reported that substantial costs
were incurred because of the time and transport re-
quired to access treatment, even though 70% of patients
included in the study were living within an hour’s walk-
ing distance of the clinic [27]. Some of these findings are
supported by another primary study from Ethiopia [28]
showing that the costs of TB diagnosis incurred by pa-
tients and escorts represent a considerable portion of
their monthly income. These costs are associated with
expenses related to diagnostic tests, but even more with
time lost in seeking care, which causes loss of income.
Norway
In Oslo/Akershus, Norway, all TB patients received
DOT without prior selective appraisal. The treatment
was organized through the home-based nursing services
and patients received DOT in their homes on a daily
basis for six months. Patients and health personnel re-
lated that because of high turnover and lack of qualified
personnel, those executing DOT were often unskilled
and there was a lack of continuity. Health personnel
were often delayed, and there was poor compliance with
routines intended to ensure that the medication was de-
livered within a certain timeframe.
As in Ethiopia, the majority of patients experienced
DOT as rigid and inflexible and felt that they had no
power to influence their own situation. Men in particu-
lar described DOT as humiliating, and related this to the
powerlessness they felt by having to accept a treatment
that interfered with their social and working life. Patients’
immigrant status was described as a factor making people
reluctant to question the treatment. In particular, asylum
seekers found it difficult to express opposition because of
the situation they were in. Those who did oppose DOT by
asking to administer the medicines themselves experi-
enced subtle threats, such as the involvement of author-
ities, including the police. Others reported how they had
been denied flexible solutions such as pill dispensers, al-
ternative DOT providers or the possibility of keeping their
medication at home, so that they could take the tablets
and leave for work if the nurses were late or did not come.
Some patients had experienced anger and hostility from
nurses because they did not have a permanent address (in-
voluntary movement between residences conflicts with
DOT). One patient reported being denied the completion
of her treatment because her frequent changes of address
made her “too difficult” to treat.
Those who had jobs or attended school found that the
lack of flexibility in how the treatment was organized
had high social costs. A majority of patients did not have a
permanent job, but had temporary engagements involving
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basis. These conditions caused a vulnerability that partici-
pants sought to compensate for by presenting themselves
as punctual but flexible shift workers, qualities that were
difficult to demonstrate because of the daily DOTarrange-
ment. Many told that they had reduced the number of
shifts they were working. This because they in the period
of receiving DOT (6 months) only were able to accept
evening shifts due to the nurses coming to their homes
within a widely defined timeframe, such as between nine
and twelve o’clock in the morning.
Many also experienced an unfortunate economic situ-
ation during the diagnostic process. Those who had been
engaged only in non-permanent work were often not
able to claim sick leave. Several had to reduce their
number of shifts gradually because of their weakened
general condition, resulting in loss of income. Others de-
scribed difficulties with receiving money through social
services after they had been diagnosed, either because
their work was not documented or because their previ-
ous income was based on day-to-day work agreements.
We found striking similarities between how DOT was
experienced in Ethiopia and Norway and how the
organization of treatment affects certain patient groups.
The two cases raise a series of ethical issues that we will
elaborate on in further detail.
Loss of autonomy
In both countries, patients with TB were deprived of
their autonomy and lacked the opportunity to influence
the delivery of their own health care. Patients were never
given reasons why their treatment was organized in such
a way, and nor was the inherent element of force or
involuntariness ever explained or justified [18]. On the
contrary, in both contexts, there was a tendency that
those who argued or asked about the rationale behind
their treatment received incomprehensible or misleading
explanations, were rejected, or even threatened. Further-
more, even though the implementation of treatment was
supposed to be driven by a rigid set of rules, there was
ambiguity in the discrepancy between what was required
by the patients and how the treatment was provided by
health personnel. Discontinuity, unpredictability and even
neglect often characterized the services of those executing
DOT. In cases where treatment was interrupted, patients
had asked for permission to store and administer their
medicines to prevent loss of employment. However, des-
pite patients being forced to give up work, income oppor-
tunities or even treatment, health personnel “naturally”
remained in possession of their medications. Many studies
show that health personnel are aware that lack of individ-
ual adjustments may force patients to choose between
treatment and other important needs [29]. However, as in
Ethiopia and Norway, there are still many examples ofhealth personnel responding to such needs by the use of
threats, scolding and increased rigidity [29]. Studies show
that health professionals commonly remain in control of
patients’ treatment cards and drug supply, a practice that
can be experienced as negative and dehumanizing by pa-
tients [30]. The two cases, supported by similar studies,
show that those practising DOT do not seem to relate
their practice to ethical considerations such as least in-
fringement or other moral concerns, one of the justifica-
tory conditions proposed by Childress et al. [18]. On the
contrary, it appears that a rule-based approach such as
DOT discourages critical thinking and sound judgment
among health personnel. The main ethical challenges,
therefore, may not be reflected in the principles behind
DOT, but rather in how these principles are interpreted
and implemented by programme planners and local health
care workers.
Burdens on the socially disadvantaged
In Ethiopia, those who were the most vulnerable and
disadvantaged, such as the very poor, single mothers,
and working immigrants from rural areas, were the ones
who struggled most to live up to the demands of treat-
ment. In Norway, the social costs experienced by pa-
tients were not comparable to the costs suffered by
patients in Ethiopia. However, also in Norway, the most
vulnerable and disadvantaged patients, such as those
without permanent jobs, were those who had the
greatest difficulty in adapting to DOT. This group of pa-
tients suffered disproportionate burdens in terms of in-
direct costs, constraints on autonomy, and violation of
dignity. In high-burden countries, the average cost of re-
ceiving TB diagnosis and treatment is estimated to drain
20–40% of annual family income, a figure that increases
greatly for the poorest [9]. A recent systematic review
assessing patient costs for TB treatment and care in sub-
Saharan Africa found TB treatment and care-related
costs to be “catastrophic” for many households. The
costs incurred by patients were equivalent to 10% or
more of per capita income in the countries where the
primary studies included in this review were carried out
[26]. The review concludes that to prevent poverty as a
consequence of TB treatment, policies that decrease dir-
ect and indirect costs are urgently needed. Several stud-
ies have documented that indirect costs, such as use of
time and transport expenses, may have a huge impact
on the ability to complete treatment, and patients may
feel forced to choose between daily treatment (DOT)
and daily work or other pressing duties [29].
We can use ethical principles such as ensuring the
common good, effectiveness, balancing benefits and bur-
dens, and respecting patients’ autonomy, or we can look
at these cases through the concept of social justice. Ei-
ther way, there are several incongruities between the
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TB control programme, such as “reduce human suffering
and the socio-economic burden associated with TB”,
“protect poor and vulnerable populations from TB, TB/
HIV, and multidrug-resistant TB”; and “protect and pro-
mote human rights in TB prevention, care and control”
[13], and the way the treatment system is implemented
and administered in practice. There seems to be a dis-
crepancy between the intention behind DOT and the
way it is implemented in programmes and by health
workers. Because of the burden imposed on the most vul-
nerable patients, we claim that there is an unfair distribu-
tion of benefits and burdens, and this unfair distribution
may increase human suffering and the socio-economic
burdens associated with TB. Several basic human rights
are disregarded [31], including the right to express opin-
ions (Human Right Article 19), the right to work and to
be protected from unemployment (Human Right Article
23), the right to medical care and necessary social services
(Human Right Article 25), the right not to be subjected to
degrading treatment (Human Right Article 5), and the list
could be extended. The undue burden imposed on socially
disadvantaged groups and the many risks to other moral
claims underline the need not only to scrutinize this treat-
ment practice but also to address why there are so few
critical voices to be heard. One might ask whether the re-
sponses of health personnel would have been similar
across cultures if the recipients of these services did not
represent socially disadvantaged groups.
Effectiveness, evidence and least restrictive means
We lack evidence that the provision of DOT by health
personnel improves cure or treatment completion rates
[10] when compared with other means of treatment, and
hence we question the degree to which the principle of
effectiveness and the related principles of proportionality
and necessity have been adequately addressed. It is diffi-
cult to see that DOT is effective or doing more good
than harm when patients who interrupt treatment risk
being excluded from further treatment and follow-up be-
cause they cannot adjust to the rules of the system. We
also question whether the potential benefits of DOT out-
weigh negative features if patients are denied the oppor-
tunity to optimize their health while receiving treatment.
Similarly, we ask whether a measure such as DOT is
doing more harm than good in the long run, if patients
lose their jobs or social positions.
In a critical review of the evidence, ethics and effective-
ness of the management of TB, Verma et al. [11] emphasize
the principle of effectiveness and the principle of least
restrictive means. They argue that the lack of solid evidence
combined with neglect of use of least restrictive means
is particularly problematic when socially disadvantaged
populations are targeted. When already vulnerablesegments of the population are involved, the evidence
should be stronger to demonstrate that the programme
will attain its goals [11].
Even though there is a lack of evidence for the effective-
ness of DOT, and increasing evidence that DOT creates
barriers for socially disadvantaged groups, standardized
DOT has been implemented without considering least
restrictive means in contexts as different as Ethiopia and
Norway. Least restrictive means implies that efforts are
implemented according to a continuum, where self-
management represents the least restrictive means and su-
pervised treatment on a daily basis represents the other
end of the spectrum of restriction [11]. Coker [2] argues
that practising least restrictive means implies that “people
must be allowed to fail before being condemned for that
failure”. Doyal [32] has a similar point, claiming that in-
fringement of patient autonomy can only be justified if
every effort has been made to optimize the success of
treatment without such infringement.
The two cases show that efforts are not being made to
optimize the success of treatment without violation of
patient autonomy, even in a low-endemic, high-income
context such as Norway. Patients who clearly express
their will to initiate and adhere to TB treatment are
forced into a treatment regimen without being allowed
to display their willingness and capability to adhere to
treatment [2]. This dimension of DOT challenges the
ethics inherent in the principles governing this treatment
programme. However, again we see tension in the dy-
namics between the overall principles of DOT and its in-
terpretation and implementation in local programmes
and by health workers. Hall [33] underlines that even if
people surrender some degree of autonomy in exchange
for membership in a community, parts of their individ-
ual autonomy will still remain. A practice where patients
adhere to supervised TB treatment but experience pun-
ishment for being delayed when collecting their medica-
tion is an example of how such residual autonomy is left
out of the equation. A practice where patients are not
allowed to keep a supply of their own medication and as
a consequence experience daily disruptions in their em-
ployment is an example of how least restrictive means
does not seem to be part of the ethical judgments being
made by health workers.
Transient reciprocity caused by inadequate moral
involvement?
It follows from the principle of reciprocity that if per-
sons experience a loss of autonomy to protect the com-
munity, the community should reciprocate by ensuring
that they are compensated for burdens such as use of
time or loss of income [20]. There is scant regard for
reciprocity in practices so rigid that patients cannot
combine treatment with daily work, or where they have
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ter how ill they are. The two cases demonstrate that the
principle of reciprocity receives little attention, which is
surprising because reciprocity should be considered not
only as compensation but also as an assurance of adher-
ence, and subsequently an element of effectiveness. One
might argue that it is just to treat everyone in the same
way, but a standardized programme that violates pa-
tients’ autonomy might, first of all, confirm that the
patients are poor and powerless and potentially to be
blamed for their own condition. It seems fair to ask
whether neglect of attending to basic ethical principles is
legitimized and facilitated by the receivers of the treat-
ment representing a group without power. A related
question is whether the disregard of heavy burdens im-
posed on socially disadvantaged patients is justified by
similar power structures, or whether there is simply
inadequate moral involvement. Numerous studies indi-
cate that poor follow-up and maltreatment by health
personnel is a problem [29] and TB patients’ social pro-
file and status as “the other” might be a reason [34].
Benatar [35] suggests that concerns about those who are
poor and suffer from ill health are transient, not only
because they are out of sight but also because their lives
may be less highly valued.
Societies may respond to a threat such as an infectious
disease by declaring a “state of emergency”, with subse-
quent restrictions on or withdrawal of individual rights
[36]. In public health discourse, socially advantaged pop-
ulations (corresponding to middle and upper classes)
have historically been portrayed as possessing the valued
qualities of self-denial and self-efficacy. Socially disad-
vantaged groups (corresponding to the working and
under classes) have tended to be pictured as dirty, lazy,
immoral, and without the capacity to resist their inclina-
tions [37]. Subsequently, different types of “disciplinary
measures”, including coercive measures, have been di-
rected towards the socially disadvantaged and less power-
ful members of society. As Lupton [37] points out, public
health efforts have also been increasingly directed towards
maintaining the boundaries of populations, preventing
those living within the border from being infected from
those coming from the outside. Thus, groups labelled as
“dirty”, “contagious”; “high-risk” and “in need of extra
surveillance”, have, for centuries and up to the present
day, corresponded with the poor, the working class and
immigrants [37].
Another interesting explanation for the lack of ethical
reflection related to treatment of infectious diseases is the
misperception that the questions it potentially raises are
simply too easy [34]. Most people would agree that more
should be done to ensure access to AIDS and TB treat-
ment, for example. At first glance, these types of questions
appear to lack the deep philosophical significance thatcharacterizes discussions related to abortion or eu-
thanasia, for example. However, as demonstrated in this
paper, there are many complex and intertwined ethical
issues that need to be addressed. The fact that diseases
such as TB primarily affect those who are vulnerable be-
cause of poverty or lack of power addresses questions of
philosophical significance. The strong association be-
tween infectious diseases and poverty makes TB a topic
of international distributive justice, where reciprocity is
one of the values with moral significance within this dis-
cussion [34,38].
Social justice in TB control and care—a way forward
The social justice perspective draws attention to the
underlying, multifaceted primary causes of disease and
the existence of inequalities in society [13,24]. TB is a
disease associated with poverty and systematic disadvan-
tage among certain groups [39], and, as suggested by the
social justice perspective, systematic disadvantages can
only be met with systematic responses [24]. If justice is
to be outcome oriented, the underlying structural causes
that makes certain groups more vulnerable to TB infec-
tion need to be addressed. The Stop TB Strategy ac-
knowledges that various social factors put certain groups
at risk of developing TB. There are also recommenda-
tions on how to provide these groups with effective
treatment. In the Guidance on Ethics of Tuberculosis
Prevention, Care and Control it is stated that, because of
the role of poverty and poverty-related factors in increasing
the risk of TB infection and progression to active disease,
“the pursuit of social justice must now become a key com-
ponent of TB control” [13]. However, there are no explicit
strategies about how to address the macro-level factors
that make these groups vulnerable. From a social justice
perspective, the fact that many TB patients are particularly
vulnerable should encourage a more persistent and con-
crete approach towards addressing socio-economic dispar-
ities and constructing programmes and plans that would
reduce, and not reinforce, some of the most evident inequi-
ties [24]. However, during the last decades, reforms in the
health sector in general have been under the strong influ-
ence of global changes in macroeconomic politics. The
reforms have encouraged increased use of cost sharing,
payment according to input factors, and prioritizing cost-
effective medical interventions [40,41]. Uncontrolled com-
modification of health and commercialization of health
services are linked with increased medicalization of human
and social relations and the growing division between the
over- and under-utilization of health services by the rich
and the poor. The inverse care law [42] states that the
availability of good medical or social care tends to vary
inversely with the needs of the population being served. As
addressed earlier in this paper, it is important to recognize
systemic inequities within all health systems [9].
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ance of addressing the needs of socially disadvantaged
populations. However, a uniform target-driven approach
that does not seek to help patients in managing burdens
related to treatment may cause extra burdens for people
who are socially disadvantaged; in addition, short term
benefits may not be sustainable. Our studies show that a
variety of social and economic costs and other burdens
change and interplay over time, from the first symptoms
of TB and throughout the treatment process. Thus, locally
adapted services need to focus on the individual patient
and her/his life situation. To ensure that patients with TB
access treatment, get cured, and remain healthy, we must
address the complexity of causes and the coexisting and
interacting crises that follow a TB diagnosis. This can be
achieved through programmes that have a holistic and
process-oriented approach.
An important aspect of this must be to include pa-
tients in an on-going dialogue about how to manage
treatment and restore their health in a sustainable way.
Programmes with approaches based on strategies that
reduce autonomy fail to empower people so that they
will gain more influence over their future health and lives.
Flexibility and options in the way the treatment is orga-
nized are essential and will not only secure manageable
solutions for patients, but also minimize the infringement
of general moral considerations, such as violation of pa-
tients’ autonomy. Today there are several examples of
programmes that are adjusted to local contexts and the
needs of individual patients [29,43]. Studies show that it
has become more common for DOT to be implemented
flexibly, such as by using lay people in the community as
DOT providers [43,44]. Examples of new ways of imple-
menting DOT in local contexts seem to recognize the
need to make the services more accessible and equitable
by providing incentives or enablers [43,45]. In South
Africa, DOT providers run soup kitchens for TB patients,
raise money to support other activities, and conduct
awareness campaigns in the community [43]. In high-
income countries in particular, there are examples of DOT
providers seeking to identify potential physical, social and
economic barriers to TB treatment, and the way of provid-
ing treatment is negotiated with each patient. In some
countries, such as the United Kingdom, DOT tends to be
used only in cases where patients are considered likely to
fail for different reasons, such as with those who are
known alcoholics [43]. In the USA, the Harlem Family
DOT Clinic is an example of a clinic that works holistic-
ally by providing consistent personal support, food, tokens
and other forms of assistance, including possible referrals
to a substance abuse counsellor, social worker or health
educator [46].
By addressing the socio-economic situation of a patient
with TB and her/his family at the point of diagnosis, wemay identify barriers to treatment adherence, as well as
barriers for remaining healthy. The potential roles of cash
transfer and microfinance interventions in tuberculosis
control have been investigated by quantifying the effects
of such measures on a selected list of TB risk factors. No
intervention specifically targeted TB, but a positive impact
on household food security was found in eight of nine
cash transfer schemes, and three of five microfinance
initiatives. Improved health care access was also docu-
mented in 10 of 12 cash transfer schemes and four of five
microfinance interventions [47]. Different enabler pack-
ages, such as provision of money to poor and vulnerable
households and individuals, could potentially prevent pa-
tients with TB from being impoverished and help protect
and build their economic, physical and human resources.
In this way, we could potentially improve access to proper
treatment and reduce people’s vulnerability to TB. Inter-
ventions including provision of money could be uncondi-
tional, or related to behavioural requirements such as
completion of treatment or school enrolment [47]. Other
measures might include the removal of user fees for TB
diagnosis and transport subsidies. An earlier cross-
sectional study from Haiti showed an improvement in
mortality and cure rates when supplementary food and
income were provided to patients undergoing TB treat-
ment [48]. Making food or income support an integral
part of TB treatment can be an important step in ad-
dressing the needs of socially disadvantaged patients.
However, to be able to advance our understanding of
the role of social determinants of TB, we need more
studies exploring the impact of socio-economic inter-
ventions that address specific TB risk factors. Further-
more, there is a need to design studies that explore how
socio-economic interventions can be addressed within
the framework of treatment programmes based on the
biomedical model.
In line with the ideals of social justice is the concept
of citizenship, defined by Marshall [49] as being a “full
member of society”. The concept was developed as a re-
sponse to a society where the poor and otherwise so-
cially disadvantaged groups had to receive attention and
gifts from the more affluent. One of the ideas behind
citizenship is that all members of the society should ex-
perience that they are true citizens, and hence the soci-
ety as a whole has to adjust for and contribute to this.
Being a true citizen includes having equal civil and polit-
ical rights and enabling each individual to influence his
or her own situation. Within the perspective of citizen-
ship, the health professions are among those that are there
to help realize the rights and opportunities of those who
are socially disadvantaged [50]. However, as seen in the
examples provided in this article, health personnel tend to
focus more on achieving short-term goals by the use of
disciplinary measures, rather than preserving citizenship.
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A rigid practice of directly observed treatment imposes
extra burdens on already vulnerable patients, may be
counterproductive, and is therefore difficult to justify from
an ethical perspective. We argue that responsiveness to
social determinants of TB should become an integral part
of the WHO TB Control Strategy. Lessening the vulner-
ability of socially disadvantaged people by intervening
through TB control programmes can reduce the unequal
consequences of ill health and prevent further impoverish-
ment and injustice among disadvantaged populations. Ex-
plicit and innovative strategies on how to integrate and
address their needs are therefore necessary.
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